Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.
The efficacy, safety, and tolerability of the mid-potency corticosteroid, fluticasone propionate ointment, 0.005%, were compared with those of a high-potency corticosteroid, betamethasone-17,21-dipropionate ointment, 0.05%, in a twelve-week randomized, double-blind, parallel-group, multicenter study of seventy-four patients with moderate-to-severe psoriasis. Efficacy was evaluated for four weeks; safety was evaluated over a twelve-week period. Fluticasone ointment, 0.005%, was not significantly different from betamethasone ointment, 0.05%, at day 15 (P = 0.147), at the end of treatment analysis (P = 0.245), or at day 29 (P = 0.154). Neither medication resulted in any abnormal laboratory values over the twelve-week study period, including plasma cortisol levels. Both medications were well tolerated.